February 6th, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that Dr. Ricardo Rivera Acevedo, a scientist within its research arm, Cannevert Therapeutics Ltd., has been invited to attend the Masterclass on Medicinal Cannabis in Leiden, The Netherlands from March 5-10, 2017.

Bedrocan, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s, hosts this 5-day seminar yearly.  The selection process involves selecting from an international pool of applicants with diverse backgrounds and research interests from the industry.  Bedocran’s Head of Research and Education, Dr. Arno Hazekamp, has brought together several world experts to review the historical significance, regulatory status, chemical composition, clinical research designs, quality control/assurance matters, and latest cultivation techniques related to medicinal cannabis.

Veritas CEO, Dr. Lui Franciosi stated that “We are very pleased to have one of the Cannevert scientists attend this event. It demonstrates Bedrocan’s interest in our scientific approach of using functional techniques to assess the potential of whole plant extracts for specific disease conditions.  This event will maximize the exchange of best practices between professionals, including policy makers, who are actively involved in the medicinal cannabis industry.”

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

About Cannevert Therapeutics Ltd.

CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $1,250,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!